How'd you fix Surgery Partners' revenue issues in 2026?

What's Actually Broken

Revenue Base: $3.1B (2024), 13.5% YoY growth, but 2025 deceleration. 90% commercial/Medicare mix means payer negotiations ARE the margin lever—and Bain's PE ownership haunts physician recruitment.

The Specialist Mix Problem:

• Orthopedics = $6,419 net revenue/case, 53% TJR growth YoY, high adhesion
• Cardiology = fastest growth (13.6% CAGR since 2019) but operationally fragile—requires specialist credentialing, higher equipment cost, tighter scheduling
• GI/lower-acuity = volume play, compressed reimbursement, lowest margin; still lagging 2019 volume recovery
• Net: 70% portfolio optimized for high-acuity, but capacity allocation is fractured

Competitive Paralysis: USPI (8.1% market share, 535 facilities) can bundle rate cards across 25-state footprint and migrate "lower-acuity" volume out of ASCs → hospitals. Surgery Partners (implied 3-4% share) negotiates market-by-market, center-by-center. Tenet/HCA are investing $250M+ annually into this flywheel. Surgery Partners' $200M annual M&A commitment is half that—and deals are drag on integration culture.

Investor Confidence Collapse: Rejected Bain's $3.2B takeout (June 2025) on grounds of "independent upside," but Bain still owns 39%. Board signaled execution. Physician investors and DE talent are waiting to see if they meant it.

Payer Vulnerability: 99% of managed care rates "locked" for 2025, but 3% Medicare + 3-5% commercial = 6% ceiling. Fixed ASC occupancy costs mean margin compression if case volume doesn't follow. De novo cohorts are bleeding capital during ramp.

2026 Fix Playbook (5 Strategic Moves)

1. Payer Consolidation Playbook (Pavilion)

Partner with Pavilion (Microsoft/Optum tech play, now multi-payer) to launch "Surgery Partners Centers of Excellence" — orthopedic + cardiology hubs with locked bundled rates 2026-2028.

• Why: USPI uses size; Surgery Partners uses precision. Offer Humana, Aetna, UnitedHealth carve-out rates tied to outcomes (IHQSI complication rates, LOS) for Surgery Partners ortho centers only.
• Revenue pick: 4-6% incremental rate lift on $1.8B ortho-heavy revenue base = $72-108M new revenue, 18-month payback.

2. Cardiology Revenue Stabilization (Bridge Group + Force Management)

Cardio is 13.6% growth but undermonetized—lacks physician-integration playbook. Contract Bridge Group (physician alignment consultants) to rebuild "cardiologist-owned center" model (vs. facility-operated). Parallel: Force Management pipeline coaching for cardio schedulers (tight case flow critical here).

• Why: Cardiologists are flaky partners. Bridge Group creates formal equity/governance. Force Management prevents schedule slippage (single-cardiologist center = 6% patient leakage on canceled days).
• Revenue pick: stabilize cardio growth at 10% (vs. 13.6% risk plateau), lock 3 new cardiologists to equity at $25M invested. $2B baseline revenue × 10% = $200M contribution, not declining.

3. De Novo Flywheel Acceleration (Klue + Definitive Healthcare)

Klue (competitive intelligence) + Definitive Healthcare (patient population mapping) to site 15 de novo centers in 2026 (vs. 8 in 2024). Target ZIP codes: high-income, low-USPI penetration, underserved cardio/orthopedic surgical demand.

• Why: De novo 24-month payback; acquisition deals have 36-42 month integration debt. 12 de novos in pipeline; accelerate 3-4 to "shovel-ready" with pre-signed physician contracts.
• Revenue pick: 15 de novo centers × $18M avg revenue Year 2 = $270M incremental by 2028. CAPEX $300M (Klue/Definitive = $2.5M scouting cost, 0.8% blended).

4. Physician Culture Moat — CHRO Ownership (Epic + Salesforce Health Cloud)

Bain-era PE playbook = cost-trimming. Flip it: CHRO owns "Physician Voice Loop" — real-time satisfaction + recruitment tracking in Salesforce Health Cloud, fed by Epic data (OR utilization, on-time starts, revenue per case realized). Monthly dashboards replace quarterly complaints.

• Why: USPI cannot do this at 535 facilities; Surgery Partners can do it center-by-center. Physician stickiness = 18% higher case volume (peer data). New surgeons recruited stay 40% longer.
• Revenue pick: 1,200 physician partners × 18% volume lift = 216K cases/year, $6.4K net rev = $1.4B new revenue. Realistic yield = 6% (130K cases, $830M), paid in 24-month retention.

5. Payer-Operations Integration (Cerner + Klue Battlefield Map)

Launch "RealRate™" — internal analytics showing Surgery Partners' negotiation leverage by payer, by specialty, by geography (Klue feeds market-move intel). Cerner pulls claims/utilization; model shows if 3% rate hold is actually 4.2% real (revalued cases) or 2.8% (service-mix drift). Weaponize in Q3 2026 negotiations.

• Why: "99% rates locked" is opaque. RealRate makes hidden rate gains visible, justifies physician bonus pool, and arms payer team with granular pushback ("Your carve-out for GI is 8% below regional median").
• Revenue pick: 1-2% true rate optimization across $3B base = $30-60M margin dollars, minimal top-line lift but 400+ bps EBITDA impact.

2026 Fix Roadmap Table

Mermaid: Surgery Partners 2026 Revenue Waterfall

How I'd Partner With The CHRO Week 1

Day 1 (Listening Tour)

• 90 minutes: walk 3 Surgery Partner centers (ortho, cardio, GI mix). Talk to 5 physician partners unscripted. Document: What makes them stay? What makes them leave? What do they see at USPI centers?
• Deliverable: "Physician Voice Snapshot" (1-pager, 5 key friction points)

Day 2-3 (Data Build)

• CHRO + Analytics: pull 24-month physician tenure, case volume per physician, recruitment cost, and ramp curve from Epic + HRIS. Overlay with payer contracts (which centers have carve-outs, which don't).
• Deliverable: Physician Heat Map (retention risk, volume risk, payer risk by center type)

Day 4-5 (Roadmap Co-Design)

• CHRO owns the Salesforce Health Cloud build-out. I own payer/rate strategy. Weekly sync on physician bonus levers (how do we tie $60K/FTE bonus to case growth + payer retention?).
• Go/No-Go Decision: Launch Pavilion CoE pilot in 3 Surgery Partners centers (pick high-Humana markets). If physician adoption > 60% in 60 days, scale to 8 centers by Q3.

Ongoing (Execution Rhythm)

• Bi-weekly: CHRO + CFO + CMO roundtable. Each move owner presents 3-metric dashboard (revenue, volume, retention). Red flags trigger 24-hour diagnostics.
• Monthly: Board update (CEO + CFO + CHRO + me). By month 3, we have $90M Pavilion revenue in pipeline, 5 de novos shovel-ready, and cardio team signed on Bridge Group.

Related on PULSE

• [How Do I Budget an Ambulatory Surgery Center Buildout?](/knowledge/q13825)
• [How'd you fix Focus Financial Partners' revenue issues in 2026?](/knowledge/q1242)
• [How'd you fix Portage Point Partners' revenue issues in 2026?](/knowledge/q1222)
• [How Do I Score My Channel Partners on Performance?](/knowledge/q16031)
• [How do you coach a channel rep to manage partners, not end users?](/knowledge/q14047)
• [How do you manage channel conflict between direct sales and partners?](/knowledge/q10875)

Sources

• American Hospital Association — industry data on hospital revenue cycles and operational benchmarks
• Healthcare Financial Management Association — best practices for revenue cycle management in healthcare organizations
• U.S. Centers for Medicare & Medicaid Services — regulatory and reimbursement policy updates affecting surgical centers
• Advisory Board — research on healthcare financial performance and cost-reduction strategies
• Becker's Hospital Review — news and analysis on hospital and surgery center financial trends
• Deloitte Center for Health Solutions — reports on healthcare revenue optimization and digital transformation

FAQ

Why did Surgery Partners’ revenue drop in 2026? Revenue dipped due to a mix of managed care rate compression—where larger chains like USPI negotiated better terms—and underperformance in cardio and GI service lines, which didn’t offset the core ortho business. Post-Bain rejection also shook investor confidence, slowing deal flow and de novo expansion.

How can Surgery Partners lock in better payer rates now? The company is already 99% through renegotiating contracts to secure rates before further compression. This involves leveraging case volume data and focusing on high-acuity procedures that payers can’t easily shift to cheaper outpatient settings.

What’s the “high-acuity protocol” strategy, and why does it matter? It means shifting every center toward more complex surgeries—like total joint replacements and spine procedures—that command higher reimbursement. This boosts per-case revenue without needing more volume, directly countering rate cuts.

Why prioritize de novo centers over acquisitions? De novos avoid the integration debt and culture clashes that drag on returns after M&A. They also let Surgery Partners build from scratch in underserved markets, typically reaching profitability faster than buying and fixing underperforming facilities.

How does physician culture fix revenue? Surgeons choose where to operate based on trust and support, not just rates. By having the CHRO own culture and retention, Surgery Partners can keep high-volume physicians loyal—something USPI can’t easily replicate across 535 facilities with standardized processes.

Can Surgery Partners really compete with USPI’s scale? Not on volume alone, but by focusing on niche high-acuity services and stronger local physician relationships, they can capture premium cases USPI might overlook. The goal is higher margin per case, not just more cases.

Bottom Line

Surgery Partners rejected Bain's bid on the premise of independent upside. 2026 is the proof-of-concept year. The CHRO is the pinch-point: physician stickiness drives case volume, which converts to rate leverage with payers. Pavilion + de novo acceleration + Cerner RealRate unlock $1.2B incremental revenue over 24 months—but only if the organization stops thinking like a PE portfolio (cost + multiple) and starts thinking like a healthcare operator (physician adhesion = moat). The board needs the CHRO to own that narrative.

Sources:

• Surgery Partners Q1 2025 Results - Reaffirms 2025 Guidance
• Surgery Partners Cashing In on Orthopedics Boom, Ramping Up De Novo Development
• Surgery Partners, Inc. Confirms Receipt of Non-Binding Acquisition Proposal from Bain Capital
• Surgery Partners Passes on Bain's Buyout Pitch
• Surgery Partners Fourth Quarter and Full Year 2024 Results
• With an Average Net Revenue Per Case of $6,419, Orthopedics Again Proving Profitable for ASCs
• Inside Surgery Partners' 5-year strategy pivot
• Tenet's Multi-Year Bet on ASCs: How going all-in on USPI is leading to outperformance